In a meta-analysis assessing the predictive and prognostic value of KRAS mutations in CRC patients treated with cetuximab, it was concluded that mCRC patients with mutated KRAS could have worse PFS and OS when treated with cetuximab [28]. Here, KRAS is linked to colorectal carcinoma.